Treatment success rate for patients treated for MDR-TB in Latvia

Latvia: Treatment success rate for patients treated for MDR-TB was 0.0% in 2022. ▼ Falling

Latest (2022)
0.0%
World rank
159th
of 163 countries
All-time high
72.0%
in 2014
All-time low
0.0%
in 2022
Years of data
11
2006–2022

Treatment success rate for patients treated for MDR-TB in Latvia, 2006–2022

0204060802006201420222006: 612007: 612008: 622009: 592010: 662011: 552012: 632013: 672014: 722015: 662022: 0

Source: World Health Organization, Global Health Observatory.

Analysis

The most recent figure for treatment success rate for patients treated for mdr-tb in Latvia is 0.0%, measured in 2022. That is the lowest value across all 11 years on record.

That represents a change of down 100.0% over ten years.

Over the whole period, treatment success rate for patients treated for mdr-tb in Latvia peaked at 72.0% in 2014 and was at its lowest, 0.0%, in 2022.

Latvia ranks 159th of 163 countries on this measure, in the bottom quarter.

The long-run direction has been consistently falling across the 11 years of available data.

Treatment success rate for patients treated for MDR-TB in Latvia, year by year

Annual values for Treatment success rate for patients treated for MDR-TB (%) in Latvia, 2006 to 2022.
Year Value Change
2006 61.0%
2007 61.0% +0.0%
2008 62.0% +1.6%
2009 59.0% -4.8%
2010 66.0% +11.9%
2011 55.0% -16.7%
2012 63.0% +14.5%
2013 67.0% +6.3%
2014 72.0% +7.5%
2015 66.0% -8.3%
2022 0.0% -100.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 60.8% 59.0% 62.0% 4
2010s 64.8% 55.0% 72.0% 6
2020s 0.0% 0.0% 0.0% 1

Countries ranked near Latvia

  1. 156 Poland 23.0% compare
  2. 157 Bahrain 17.0% compare
  3. 158 France 3.0% compare
  4. 159 Maldives 0.0% compare
  5. 159 Oman 0.0% compare
  6. 159 Angola 0.0% compare
  7. 159 Marshall Islands 0.0% compare

See the full ranking of 175 places →

More health data for Latvia

All data for Latvia →

Frequently asked questions

What is treatment success rate for patients treated for mdr-tb in Latvia?
Treatment success rate for patients treated for mdr-tb in Latvia was 0.0% in 2022, according to World Health Organization, Global Health Observatory.
What is the highest treatment success rate for patients treated for mdr-tb recorded in Latvia?
The highest recorded value was 72.0% in 2014.
What is the lowest treatment success rate for patients treated for mdr-tb recorded in Latvia?
The lowest recorded value was 0.0% in 2022.
How does Latvia rank for treatment success rate for patients treated for mdr-tb?
Latvia ranks 159th out of 163 countries with data for 2022.
Is treatment success rate for patients treated for mdr-tb rising or falling in Latvia?
Over the last ten years it is down 100.0%. The long-run trend across the full record is falling.
Where does this Latvia data come from?
The figures come from World Health Organization, Global Health Observatory, published as part of Treatment success rate for patients treated for MDR-TB (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 11 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).

Share, cite or embed this page

Cite this page

Treatment success rate for patients treated for MDR-TB in Latvia. Statizoid, drawing on World Health Organization, Global Health Observatory. Retrieved 06 September 2026, from https://health.statizoid.com/stat/treatment-success-rate-for-patients-treated-for-mdr-tb-percent/latvia/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY-NC-SA 3.0 IGO (WHO); please keep the attribution.

<a href="https://health.statizoid.com/stat/treatment-success-rate-for-patients-treated-for-mdr-tb-percent/latvia/">Treatment success rate for patients treated for MDR-TB in Latvia</a> — Statizoid

About this data

Indicator
Treatment success rate for patients treated for MDR-TB (%)
Source
World Health Organization, Global Health Observatory
Licence
CC BY-NC-SA 3.0 IGO (WHO)
Coverage
175 places, 2,495 data points, 1999–2022
Last refreshed